Brief: Island Pharmaceuticals Says FDA Grants Orphan Designation For Galidesivir In Marburg
Wed 02:43
BRIEF-Island Pharmaceuticals Says FDA Grants Orphan Designation For Galidesivir In Marburg June 17 (Reuters) - Island Pharmaceuticals Ltd ILA.AX:
FDA GRANTS ORPHAN DESIGNATION FOR GALIDESIVIR IN MARBURG
FDA GRANTS ORPHAN DRUG DESIGNATION TO GALIDESIVIR FOR MARBURG VIRUS DISEASE
Further company coverage: ILA.AX
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Island Pharmaceuticals
See all newsBrief: Island Pharmaceuticals Says FDA Grants Orphan Designation For Galidesivir In Marburg
Australia's Island Pharmaceuticals rises on agreement extension with US Army
Brief: Island Pharmaceuticals Says GMP Manufacturing Of Galidesivir Commenced
Australia's Island Pharmaceuticals rises on US government collaboration
Brief: Island Pharmaceuticals Seeks Trading Halt